Alvotech (NASDAQ:ALVO) Shares Break Below Two Hundred Day Moving Average – Time to Sell?

Alvotech (NASDAQ:ALVO)’s share price crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $4.20 and traded as low as $4.13. Alvotech shares last traded at $4.19, with a volume of 2,091,332 shares trading hands.

Key Headlines Impacting Alvotech

Investors following ALVO have been watching these headlines:

• Positive Sentiment: Alvotech forecast 2026 revenue of $650 million–$700 million, broadly around or above the $652.5 million consensus at the midpoint, and EBITDA of $180 million–$220 million. Management said it expects the fourth quarter to be the strongest in company history. Article: Alvotech targets $650M-$700M revenue and $180M-$220M EBITDA
• Neutral Sentiment: The earnings call highlighted growth opportunities alongside business risks; the available article summary did not specify further details. Article: Alvotech Earnings Call Highlights Growth and Risks
• Negative Sentiment: Q3 revenue of $111.6 million fell short of the $125.2 million analyst estimate. Alvotech posted a loss of $0.03 per share; while that beat one reported consensus estimate of a $0.04 loss, it missed Zacks’ estimate of a $0.01 loss. The revenue miss and mixed earnings comparisons could pressure the shares. Article: Alvotech Reports Q3 Loss, Lags Revenue Estimates

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ALVO shares. Bank of America began coverage on shares of Alvotech in a research report on Monday, August 24th. They set a “buy” rating and a $7.00 price target for the company. Zacks Research downgraded shares of Alvotech from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Evercore began coverage on shares of Alvotech in a research report on Friday, August 14th. They set an “outperform” rating for the company. UBS Group set a $8.00 target price on shares of Alvotech in a report on Wednesday, September 16th. Finally, Barclays raised shares of Alvotech from an “underweight” rating to an “overweight” rating and upped their target price for the company from $4.00 to $8.00 in a report on Wednesday, September 16th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $8.40.

Alvotech Stock Performance

The business’s fifty day simple moving average is $5.23 and its 200-day simple moving average is $4.20. The firm has a market capitalization of $1.26 billion, a PE ratio of -5.11 and a beta of 0.24.

Alvotech (NASDAQ:ALVO) last released its quarterly earnings data on Wednesday, November 11th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). The company had revenue of $111.60 million for the quarter, compared to the consensus estimate of $123.45 million. Sell-side analysts expect that Alvotech will post -0.01 earnings per share for the current fiscal year.

Institutional Trading of Alvotech

A number of institutional investors and hedge funds have recently bought and sold shares of ALVO. Citadel Advisors LLC purchased a new stake in Alvotech in the 2nd quarter worth $6,376,000. Renaissance Technologies LLC grew its position in shares of Alvotech by 146.9% during the first quarter. Renaissance Technologies LLC now owns 63,200 shares of the company’s stock valued at $217,000 after purchasing an additional 37,600 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Alvotech during the third quarter valued at about $2,326,000. State Street Corp purchased a new position in shares of Alvotech during the third quarter valued at about $594,000. Finally, Royce & Associates LP bought a new stake in shares of Alvotech in the third quarter worth about $3,817,000.

About Alvotech

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.